<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1003257026
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EMIFLOC 500 mg Film-coated Tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        29.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GLOBAL PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 423]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            MANAYER NAJD TRADING MEDICAL NEEDS CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GLOBAL PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Emifloc contains a medicine called levofloxacin. This belongs to a group of medicines called &nbsp;&lsquo;quinolone&rsquo; antibiotics. It works by killing the bacteria that cause infections in your body.</p><p>Emifloc can be used to treat infections of the:</p><p>&bull; Sinuses</p><p>&bull; Lungs, in people with long-term breathing problems or pneumonia</p><p>&bull; Urinary tract, including your kidneys or bladder</p><p>&bull; Prostate gland, where you have a long lasting infection.</p><p>&bull; Skin and underneath the skin, including muscles. This is sometimes called &lsquo;soft tissue&rsquo;.</p><p>In some special situations, Levofloxacin Tablets may be used to lessen the chances of getting a pulmonary disease named anthrax or worsening of the disease after you are exposed to the bacteria causing anthrax.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take this medicine and tell your doctor if:</p><p>&bull; You are allergic to levofloxacin, any other quinolone antibiotic such as moxifloxacin, ciprofloxacin or ofloxacin or any of the other ingredients of Emifloc (listed in section 6).</p><p>&bull; Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue.</p><p>&bull; You are a child or a growing teenager.</p><p>&bull; You are pregnant, might become pregnant or think you may be pregnant or are breast-feeding.</p><p>&bull; You have ever had a problem with your tendons such as tendonitis that was related to treatment with a &lsquo;quinolone antibiotic&rsquo;. A tendon is the cord that joins your muscle to your skeleton</p><p>&bull; You have ever had epilepsy.</p><p>Do not take this medicine if any of the above applies to you. If you are not sure, talk to your doctor or pharmacist before taking Emifloc.</p><p>Take special care with Emifloc Check with your doctor or pharmacist before taking your medicine if:</p><p>&bull; You have ever had Heart problems :Caution should be taken when using this kind of medicine, if you were born with or have family history of prolonged QT interval (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially low level of potassium or magnesium in the blood), have a very slow heart rhythm (called &lsquo;bradycardia&rsquo;), have a weak heart (heart failure), have ahistory of heart attack (myocardial infarction), you are female or elderly or you are taking other medicines that result in abnormal ECG changes (see section Other medicines and Levofloxacin Tablets).</p><p>&bull; You are 60 years of age or older</p><p>&bull; You are diabetic.</p><p>&bull; You have kidney problems and/or ever has liver problems</p><p>&bull; You have ever had mental health problems or a fit (seizure)</p><p>&bull; You have had damage to your brain due to a stroke or other brain injury</p><p>&bull; You are using corticosteroids, sometimes called steroids (see section &ldquo;Taking Other medicines&rdquo;)</p><p>&bull; You have &lsquo;glucose &ndash; 6 &ndash; phosphate dehydrogenase deficiency&rsquo;. You are more likely to have serious problems with your blood when taking this medicine</p><p>&bull; You have myasthenia gravis</p><p>If you are not sure if any of the above applies to you, talk to your doctor or pharmacist before taking Emifloc. Taking Emifloc with other medicines</p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines including herbal medicines. This is because Emifloc can affect the way some other medicines work. Also some medicines can affect the way Emifloc work.</p><p>In particular, tell your doctor if you are taking any of the following medicines. This is because it can increase the chance of you getting side effects, when taken with Emifloc:</p><p>&bull; Corticosteroids &ndash; used for inflammation. You may be more likely to have inflammation and/or</p><p>breakage of your tendons</p><p>&bull; Warfarin &ndash; used to thin the blood. You may be more likely to have a bleed. Your doctor may</p><p>need to take regular blood tests to check how well your blood can clot.</p><p>&bull; Theophylline &ndash; used for breathing problems. You are more likely to have a fit (seizure) if taken</p><p>with Emifloc</p><p>&bull; Non-steroidal anti-inflammatory drugs (NSAIDS) &ndash; used for pain and inflammation such as aspirin, ibuprofen, fenbufen, ketoprofen and indomethacin. You are more likely to have a fit (seizure) if taken with Emifloc.</p><p>&bull; Medicines known to affect the way your heart beats. This includes medicines used for abnormal heart rhythm (antiarrhythmics such as quinidine, hydroquinidine, disopyramide,</p><p>sotalol, dofetilide, ibutilide and amiodarone) , depression (tricyclic antidepressants such as</p><p>amitriptyline and imipramine), for psychiatric disorders (antipsychotics) and for bacterial infections (&lsquo;macrolide&rsquo; antibiotics such as erythromucin, azithromycin and Clarithromycin)</p><p>&bull; Probenecid &ndash; used for gout. Your doctor may want to give you a lower dose if you have</p><p>kidney problems.</p><p>&bull; Cimetidine &ndash; used for ulcers and heartburn. If you have kidney problems, doctor may suggest a lower dose.</p><p>&bull; Ciclosporin &ndash; used after organ transplants. You may be more likely to get the side effects of</p><p>ciclosporin.</p><p>Do not take Emifloc at the same time as the following medicine as it can affect the way Emifloc work:</p><p>Iron tablets (for anemia), zinc supplements, magnesium or aluminum containing antacids (for acid or heartburn), didanosine, or sucralfate (for stomach ulcers). See section 3 &ldquo;If you are already taking iron tablets, zinc supplements, antacids, didanosine or sucralfate&rdquo; below.</p><p>Urine tests for opiates</p><p>Urine tests may show &lsquo;false-positive&rsquo; results for painkillers called &lsquo;opiates&rsquo; in people taking Emifloc. If your doctor has prescribed a urine test, tell your doctor you are taking Emifloc tablets.</p><p>Tuberculosis tests</p><p>This medicine may cause &ldquo;false negative&rdquo; results for some tests used in laboratory to search for the bacteria causing tuberculosis.</p><p>Taking Emifloc with food and drink</p><p>Take without regard to meals. Take with water, drink with plenty of water. Taking this product with orange juice can result in reduced quinolone plasma levels.</p><p>Pregnancy and breast-feeding</p><p>Do not take this medicine if:</p><p>&bull; You are pregnant, might become pregnant or think you may be pregnant</p><p>&bull; You are breast-feeding or planning to breast-feed</p><p>Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or</p><p>breast-feeding.</p><p>Driving and using machines</p><p>You may get side effects after taking this medicine, including feeling dizzy, sleepy, a spinning feeling (vertigo) or changes to your eyesight. Some of these side effects can affect your concentration and your reaction speed. If this happens, do not drive or carry out any work that requires a high level of attention.</p><p>Always take Emifloc exactly as your doctor has told you.</p><p>Taking this medicine</p><p>&bull; Take this medicine by mouth; swallow the tablets whole with a drink of water</p><p>&bull; The tablets may be taken during meals or at any time between meals Protect your skin from sunlight</p><p>Keep out of direct sunlight while taking this medicine as your skin will become much more sensitive to the sun and may burn or tingle. Make sure you use high factor sun cream and wear a hat and clothes which cover your arms and legs. Avoid sun beds.</p><p>If you are already taking iron tablets, zinc supplements, antacids, didanosine or sucralfate</p><p>Do not take these medicines at the same time as Emifloc. Take your dose at least 2 hours before or after Emifloc.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Your doctor will decide on how many Emifloc you should take, depending on the type of infection you have and where the infection is in your body</p><p>&bull; The length of your treatment will depend on how serious your infection is</p><p>&bull; If you feel the effect of your medicine is too weak or strong, do not change the dose yourself, but ask your doctor</p><p>Adults and the elderly</p><p>Sinuses: One tablet of Emifloc 500 mg, once each day</p><p>Lungs infection, in people with long-term breathing problems: one tablet of Emifloc 500 mg, once each day</p><p>Pneumonia: One tablet of Emifloc 500 mg, once or twice each day</p><p>Infection of urinary tract, including your kidneys or bladder: &frac12; tablet of Emifloc 500 mg, each day</p><p>Prostate gland: One tablet of Emifloc 500 mg, once each day</p><p>Infection of skin and underneath the skin, including muscles: one tablet of Emifloc 500 mg, once or twice each day</p><p>Adults and the elderly with kidney problems</p><p>Your doctor may need to give you a lower dose.</p><p>Children and Teenagers: This medicine must not be given to children or teenagers</p><p>If you take more Emifloc than you should If you accidentally take more tablets than you should, tell a doctor or get other medical advice straight away. The following effects may happen: convulsive fits (seizures), feeling confused, dizzy, less conscious, having tremor and heart problems &ndash; leading to uneven heart beats as well as feeling sick (nausea) or having stomach burning.</p><p>If you forget to take Emifloc</p><p>If you forgot to take a dose, take it as soon as you remember unless it is nearly time for your next dose.</p><p>Do not double-up the next dose to make up for the missed dose.</p><p>If you stop taking Emifloc</p><p>Do not stop taking Emifloc just because you feel better. It is important that you complete the course of tablets that your doctor has prescribed for you. If you stop taking the tablets too soon, the infection may return, your condition may get worse or the bacteria may become resistant to the medicine. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Emifloc can cause side effects, although not everybody gets them. These effects are normally mild or moderate and often disappear after a short time.</p><p>Stop taking Emifloc and see a doctor or go to a hospital straight away if you notice the following side effect:</p><p>Very rare (may affect up to 1 in 10,000 people)</p><p>&bull; You have an allergic reaction. The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat, or tongue</p><p>Stop taking Emifloc and see a doctor straight away if you notice any of the following serious side effects</p><p>&ndash; you may need urgent medical treatment:</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>&bull; Watery diarrhoea which may have blood in it, possibly with stomach cramps and a high temperature.</p><p>These could be signs of a severe bowel problem</p><p>&bull; Pain and inflammation in your tendons or ligaments, which could lead to rupture. The Achilles</p><p>tendon is a_ected most often.</p><p>&bull; Fits (convulsions)</p><p>Very rare (may affect up to 1 in 10,000 people)</p><p>&bull; Burning, tingling, pain or numbness. These may be signs of something called &lsquo;neuropathy&rsquo;</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&bull; Severe skin rashes which may include blistering or peeling of the skin around your lips, eyes, mouth, nose and genitals. &bull; Loss of appetite, skin and eyes becoming yellow in colour, dark-coloured urine, itching, or tender stomach (abdomen). These may be signs of liver problems which may include a fatal failure of the liver.</p><p>&bull; If your eyesight becomes impaired or if you have any other eye disturbance whilst taking Emifloc, consult an eye specialist immediately.</p><p>Tell your doctor if any of the following side effects gets serious or lasts longer than a few</p><p>days:</p><p>Common (may affect up to 1 in 10 people)</p><p>&bull; Sleeping problems &bull; Headache, feeling dizzy</p><p>&bull; Feeling sick (nausea, vomiting) and diarrhoea</p><p>&bull; Increase in the level of some liver enzymes in your blood Uncommon (may affect up to 1 in 100 people)</p><p>&bull; Changes in the number of other bacteria or fungi, infection by fungi named Candida, which may need to be treated &bull; Changes in the number of white blood cells shown up in the results of some blood tests (leukopenia, eosinophilia) &bull; Feeling stressed (anxiety), feeling confused, feeling nervous, feeling sleepy, trembling, a spinning feeling (vertigo) &bull; Shortness of breath (dyspnoea). &bull; Changes in the way things taste, loss of appetite, stomach upset or indigestion (dyspepsia), pain in your stomach area, feeling bloated (flatulence) or constipation.</p><p>&bull; Itching and skin rash, severe itching or hives (urticaria), sweating too much (hyperhidrosis)</p><p>&bull; Joint pain or muscle pain &bull; Blood tests may show unusual results due to liver (bilirubin increased) or kidney (creatinine increased) problems</p><p>&bull; General weakness</p><p>Rare (may affect up to 1 in 1,000 people)</p><p>&bull; Bruising and bleeding easily due to a lowering in the number of blood platelets (thrombocytopenia).</p><p>&bull; Low number of white blood cells (neutropenia) &bull; Exaggerated immune response (hypersensitivity).</p><p>&bull; Lowering of your blood sugar levels (hypoglycaemia). This is important for people that have</p><p>diabetes.</p><p>&bull; Seeing or hearing things that are not there (hallucinations, paranoia), change in your</p><p>opinion and thoughts (psychotic reactions) with a risk of having suicidal thoughts or actions.</p><p>&nbsp;&bull;Feeling depressed, mental problems, feeling restless (agitation), abnormal dreams or nightmares.</p><p>&bull;Tingly feeling in your hands and feet (paraesthesia) &bull; Problems with your hearing (tinnitus) or</p><p>eyesight (blurred vision)</p><p>&bull; Unusual fast beating of your heart (tachycardia) or low blood pressure (hypotension).</p><p>&bull; Muscle weakness. This is important in people with myasthenia gravis (a rare disease of the nervous system).</p><p>&bull; Changes in the way your kidney works and occasional kidney failure which may be due to an allergic kidney reaction called interstitial nephritis.</p><p>&bull; Fever</p><p>Not known (frequency cannot be estimated from the available data)</p><p>&bull; Lowering in red blood cells (anemia): this can make the skin pale or yellow due to damage of the red blood cells; lowering in the number of all types of blood cells (pancytopenia)</p><p>&bull; Fever, sore throat and a general feeling of being unwell that does not go away. This may be due to a lowering in the number of white blood cells (agranulocytosis).</p><p>&bull; Loss of circulation (anaphylactic likeshock).</p><p>&bull; Increase of your blood sugar levels (hyperglycaemia) or lowering of your blood sugar levels leading to coma (hypoglycaemic coma). This is important for people that have diabetes.</p><p>&bull; Changes in the way things smell, loss of smell or taste (parosmia, anosmia, ageusia)</p><p>&bull; Problems moving and walking (dyskinesia, extrapyramidal disorders)</p><p>&bull; Temporary loss of consciousness or posture (syncope).</p><p>&bull; Temporary loss of vision, inflammation of the eye</p><p>&bull; Impairment or loss of hearing.</p><p>&bull; Abnormal fast heart rhythm, life-threatening irregular heart rhythm including cardiac arrest,alteration of the heart rhythm (called &lsquo;prolongation of QT interval&rsquo;, seen on ECG, electrical activity of the heart).</p><p>&bull; Difficulty breathing or wheezing (bronchospasm).</p><p>&bull; Allergic lung reactions.</p><p>&nbsp;&bull; Pancreatitis.</p><p>&nbsp;&bull; Inflammation of the liver (hepatitis).</p><p>&nbsp;&bull; Increased sensitivity of your skinto sun and ultraviolet light (photosensitivity)</p><p>&bull; Inflammation of the vessels that carry blood around your body due to an allergic reaction (vasculitis).</p><p>&bull; Inflammation of the tissue inside the mouth (stomatitis).</p><p>&bull; Muscle rupture and muscle destruction (rhabdomyolysis)</p><p>. &bull; Joint redness and swelling (arthritis).</p><p>&nbsp;&bull; Pain, including pain in the back, chest and Extremities</p><p>. &bull; Attacks of porphyria in people who already have porphyria (a very rare metabolic disease).</p><p>&bull; Persistent headache with or without blurred vision (benign intracranial hypertension).</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep all medicines out of the sight and reach of children. Do not store above 30&deg;C . Store in a dry place. Do not use Emifloc after the expiry date (EXP) which is stated on the carton and foil. Do not use Emifloc if you notice visible signs of deterioration. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Each film-coated tablet of Emifloc contains 500 mg of levofloxacin (as levofloxacin hemihydrate).</p><p>The other ingredients are:</p><p>&bull; For the tablet core: Microcrystalline cellulose, Colloidal Anhydrous Silica, Hypromellose,</p><p>Crospovidone, and Magnesium Stearate</p><p>&bull; For the tablet coating: Opadry Pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Emifloc is film-coated tablets for oral use. The tablets are pink in color, capsule shaped with “GP67” embossing on one side and break line on both the sides. Emifloc 500 mg FC Tablets are provided in pack sizes of 5 tablets (5’s Blister X1) or 7 tablets (7’s Blister X 1 ).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Globalpharma Co. LLC, P. O. Box 72168, Dubai, UAE</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last updated in July 2016 (11-17)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إميفلوك يحتوي على دواء يدعى ليفوفلوكساسين ، ينتمي إلى فئة المضادات الحيوية التي تسمى &quot;الكينولون&quot;. يعمل عن طريق قتل البكتيريا التي تسبب حالات خمج في جسمك.</p><p dir="RTL"><strong>دواعي استعمال إميفلوك لعلاج حالات خمج</strong><strong>:</strong></p><p dir="RTL">&bull; الجيوب الأنفية. &bull; الرئتين لدى الأشخاص المصابين بمشاكل مزمنة في التنفس أو بالإلتهاب الرئوي.</p><p dir="RTL">&bull; المسالك البولية بما فيها الكلى أو المثانة. &bull; الغدة البروستاتية عندما تكون مصابا بحالة خمج طويلة الأمد.</p><p dir="RTL">&bull; الجلد وتحت الجلد بما في ذلك العضلات ، ما يسمى عادة &quot; النسيج الرخو&quot;.</p><p dir="RTL">في بعض الحالات الخاصَّة، قد يتم استخدام أقراص ليفوفلوكساسين؛ للحد من فرص الإصابة بمرض رئوي يُسمى:</p><p dir="RTL">الجمرة الخبيثة، أو تفاقم المرض بعد تعرُّضك للبكتيريا المُسَببة للجمرة الخبيثة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول هذا الدواء وأعلم طبيبك في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&bull; اذا كنت تعاني من حساسية ضد الليفوفلوكساسين أو أي مضاد حيوي آخر من فئة الكينولون مثل موكسيفلوكساسين ، ( سيبروفلوكساسين أو اوفلوكساسين أو أي مكونات أخرى في إميفلوك (مدرجة في القسم ٦</p><p dir="RTL">&bull; تتضمن أعراض الإرتكاس التحسسي ما يلي: طفح ، مشاكل في البلع أو التنفس ، تورم الشفتين أو الوجه أو الحلق أو اللسان.</p><p dir="RTL">&bull; اذا كنت طفلا أو مراهقا في طور النمو.</p><p dir="RTL">&bull; إذا كنتِ حاملا أو قد تصبحين حاملا أو تعتقدين نفسك حاملا أو كنتِ مرضعة.</p><p dir="RTL">&bull; اذا عانيت يوما من مشكلة في الأوتار مثل التهاب الوتر الناتج عن علاج بمضاد حيوي من فئة الكينولون. الوتر هوالحبل الذي يصل عضلاتك بكهيكلك العظمي.</p><p dir="RTL">&bull; إذا أصبت يوما بالصرع.</p><p dir="RTL">لا تأخذ هذا الدواء اذا كنت تعاني من إحدى الحالات المذكورة أعلاه . إذا لم تكن واثقا إستشر طبيبك أو الصيدلي الخاص بك قبل تناول إميفلوك.</p><p dir="RTL"><strong>تحذيرات خاصة قبل تناول إميفلوك</strong></p><p dir="RTL"><strong>إستشر طبيبك أو الصيدلي الخاص بك قبل تناول هذا الدواء في الحالات التالية</strong><strong>:</strong></p><p dir="RTL">&bull; إذا أُصِبت من قبل بمشاكل في القلب: يجب توخي الحذر عند استخدام هذا النَّوع من الأدوية، إذا كنت قد وُلِدت بحالة من أو كان لديك تاريخ مرضي عائلي من هذه الحالة (تتم رؤيتها على رسم القلب الكهربائي، التَّسجيل ،QT إطالة فترة الكهربي للقلب)، إذا كان لديك اختلال في توازن الأملاح في الدَّم (لا سيما انخفاض مستوى البوتاسيوم أو الماغنسيوم في الدَّم)، إذا كان النظم القلبي لديك بطيئًا للغاية (يُسمى: &quot;بطء ضربات القلب&quot;)، إذا كان لديك ضعف بالقلب (فشل القلب)،</p><p dir="RTL">إذا كان لديك تاريخ مرضي من النَّوبة القلبية (احتشاء عضلة القلب)، إذا كنتِ سيدة، أو كنت من كبار السن، أو كنت تتناول أدوية أخرى تُؤدي إلى تغيرات غير طبيعية في رسم القلب الكهربائي (انظر قسم: تناوُل إميفلوك مع أدوية أخرى).</p><p dir="RTL">&bull; إذا كنت في ال ٦۰ من العمر أو أكثر. &bull; إذا كنت مصابا بداء السكري .</p><p dir="RTL">&bull; إذا كنت تعاني من مشاكل كلوية و/أو عانيت يوما من مشاكل في الكبد. &bull; إذا عانيت يوما من مشاكل في الصحة العقلية أو اصبت يوما بنوبة صرع.</p><p dir="RTL">&bull; إذا تعرض دماغك للضرر بسبب سكتة دماغية أو إصابة أخرى في الدماغ. &bull; إذا كنت تستعمل ستيرويدات قشرية وتسمى أحيانا ستيرويدات (انظر قسم: تناوُل إميفلوك مع أدوية أخرى).</p><p dir="RTL">&bull; إذا كنت تعاني من نقص في نازعة هيدروجين جلوكوز- ٦- فوسفات (انت اكثرعرضة للإصابة بمشاكل خطيرة في الدم عند تناول هذا الدواء</p><p dir="RTL">&bull; إذا كنت تعاني من الوهن العضلي الوبيل .</p><p dir="RTL">إذا لم تكن متأكداً مما إذا كانت تنطبق عليك إحدى الحالات أعلاه ، إستشر طبيبك أو الصيدلي الخاص بك قبل تناول إميفلوك.</p><p dir="RTL"><strong>تناوُل إميفلوك مع أدوية أخرى</strong></p><p dir="RTL">الرجاء أن تعلم طبيبك أو الصيدلي الخاص بك إذا كنت تتناول حالياً أو تناولت مؤخراً أي دواء آخر بما في ذلك الأدوية التي تشتريها بدون وصفة طبية وتتضمن الأدوية العشبية ، لأن إميفلوك يمكن أن يؤثر على كيفية عمل بعض الأدوية الأخرى كما أن بعض الأدوية يمكن أن تؤثر على كيفية عمل إميفلوك.</p><p dir="RTL"><strong>بشكل خاص ، أعلم طبيبك اذا كنت تتناول أحد الأدوية التالية لأن ذلك قد يزيد من خطر تعرضك للتأثيرات الجانبية</strong><strong> </strong><strong>عند تناول إميفلوك</strong><strong>:</strong></p><p dir="RTL">&bull; الستيرويدات القشرية وتستعمل لعلاج الإلتهابات ، فقد تزيد خطر تعرضك لإلتهاب الأوتار و/أو تمزقها.</p><p dir="RTL">&bull; الوارفارين المستعمل لترقيق الدم . فقد يزيد خطر تعرضك للنزيف . طبيبك قد يحتاج إلى إجراء فحوصات دم منتظمة للتحقق من مدى تجلط الدم.</p><p dir="RTL">&bull; الثيوفللين المستعمل لمشاكل التنفس فقد يزيد خطر تعرضك لنوبة صرع عند تناوله مع إميفلوك .</p><p dir="RTL">&bull; مضادات الإلتهاب غير الستيرويدية التي تستعمل للألم والإلتهابات مثل الأسبرين، ايبوبروفين، فينبوفين، كيتوبروفين و إندوميتاسين قد تزيد خطر تعرضك لنوبة صرع عند تناولها مع إميفلوك.</p><p dir="RTL">&bull; الأدوية التي يعرف عنها أنها تؤثر على ضربات القلب وتتضمن الأدوية المستعملة للنظم القلبي غير الطبيعي (عدم =</p><p dir="RTL">&bull; بروبينيسيد المستعمل للنقرس . قد يرغب طبيبك في إعطائك جرعة أقل إذا كان لديك مشاكل في الكلى.</p><p dir="RTL">&bull; سيميتيدين المستعمل للقرحة وحرقة القلب. إذا كنت تعاني من مشاكل في الكلى ، قد يصف طبيبك جرعة أدنى.</p><p dir="RTL">&bull; سيكلوسبورين يستعمل بعد عمليات زرع الأعضاء. قد تكون أكثر عرضة للتأثيرات الجانبية للسيكلوسبورين.</p><p dir="RTL"><strong>لاتأخذ إميفلوك في الوقت ذاته مع الأدوية التالية لأن ذلك يمكن أن يؤثرعلى طريقة عمل إميفلوك</strong><strong> :</strong></p><p dir="RTL">أقراص الحديد (لفقر الدم) ، أو مكملات الزنك ، أو مضادات الحموضة التي تحتوي على المغنيسيوم أو الألومنيوم (للحموضة أو حرقة القلب) ، أو ديدانوزين ، أو سكرالفيت (لقرحة المعدة). راجع الفقرة ۳ &quot; إذا كنت تتناول أقراص حديد أو مكملات الزنك أو مضادات حموضة أو ديدانوزين أو سكرالفيت&quot; ادناه.</p><p dir="RTL"><strong>فحوص البول للمستحضرات الافيونية</strong><strong>:</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تظهر فحوص البول نتائج &quot;إيجابية كاذبة&quot; على وجود مسكنات الألم &quot;مستحضرات أفيونية&quot; لدى المرضى الذين يتناولون إميفلوك. في حال طلب منك طبيبك إجراء فحص بول أعلمه أنك تتناول إميفلوك.</p><p dir="RTL"><strong>فحوص السل</strong><strong>:</strong></p><p dir="RTL">قد تظهر فحوص السل نتائج &quot;سلبية كاذبة&quot; في المختبر عند البحث عن البكتيريا المسببة لمرض السل.</p><p dir="RTL"><strong>تناوُل إميفلوك مع الأطعمة والمشروبات</strong></p><p dir="RTL">تناوله بصرف النَّظر عن تناوُل الوجبات من عدمه. تناوله مع الماء، اشرب كمية من الماء. يُمكِن أن يُؤدي تناوُل هذا المُنتَج مع عصير البرتقال إلى انخفاض مستويات الكينولون في البلازما.</p><p dir="RTL"><strong>الحمل والإرضاع</strong><strong>:</strong></p><p dir="RTL"><strong>لا تتناولي هذا الدواء إذا</strong><strong> :</strong></p><p dir="RTL">&bull; كنتِ حاملاً أو يمكن أن تحملي أو تعتقدين نفسك حاملاً . &bull; كنتِ مرضع أو تنوين الإرضاع .</p><p dir="RTL">إستشيري طبيبك أو الصيدلي الخاص بك قبل تناول أي دواء إذا كنتِ حاملاً أو مرضع</p><p dir="RTL"><strong>القيادة و إستعمال الآلات</strong><strong>:</strong></p><p dir="RTL">قد تتعرض لبعض التأثيرات الجانبية بعد تناول هذا الدواء بما في ذلك الشعور بالدوخة و النعاس و الدوار أو بتغييرات في النظر. و يمكن أن تؤثر بعض هذه التأثيرات الجانبيّة على قدرتك على التركيز و على سرعة ردّة الفعل لديك. في حال حصول هذا ، لا تقد سيّارة و لا تقم بأيّ عمل يتطلب مستوى عالي من الانتباه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول دائمآ إميفلوك حسب وصفة الطبيب تماما.</p><p dir="RTL"><strong>تناول هذا الدواء</strong><strong>:</strong></p><p dir="RTL">&bull; تناول هذا الدواء عبر الفم ، إبلع الأقراص كاملة مع الماء.</p><p dir="RTL">&bull; يمكن تناول الأقراص مع الطعام أو في أي وقت كان بين الوجبات .</p><p dir="RTL"><strong>إحم بشرتك من أشعة الشمس</strong><strong>:</strong></p><p dir="RTL">لاتتعرض لاشعة الشمس المباشرة خلال فترة تناولك هذا الدواء. لأن بشرتك ستصبح أكثرحساسية بكثير تجاه الشمس وقد تحترق أوتشعر بوخز خفيف . إحرص علي استعمال مرهم وقاية قوي من اشعة الشمس ، إعتمر دائماً قبعة وارتد ثياباً تغطي ذراعيك وساقيك. تجنّب حمامات الشمس.</p><p dir="RTL">إذا كنت تتناول أقراص حديد أو مكملات الزنك أو مضادات حموضة أو ديدانوزين أو سكرالفيت:</p><p dir="RTL">لاتتناول هذه الأدوية بالتزامن مع إميفلوك. خذ جرعتك من هذه الأدوية قبل أو بعد ساعتين على الأقل من تناول إميفلوك.</p><p dir="RTL"><strong>مقدار الجرعة</strong><strong>:</strong></p><p dir="RTL">&bull; سيقررطبيبك عدد أقراص إميفلوك التي عليك تناولها. تتوقف الجرعة على نوع الخمج الذي أصابك وعلى مكان هذا الخمج في جسمك.</p><p dir="RTL">&bull; تتوقف مدة علاجك على خطورة الخمج الذي تعاني منه.</p><p dir="RTL">&bull; إذا شعرت أن مفعول دوائك ضعيف جداً أوقوي جداً لا تغيرالجرعة من تلقاء نفسك بل إستشر طبيبك.</p><p dir="RTL"><strong>البالغون والمسنون</strong><strong>:</strong></p><p dir="RTL"><strong>الجيوب الأنفية: قرص </strong>إميفلوك ٥۰۰ ملجم ، مرة واحدة في اليوم.</p><p dir="RTL"><strong>التهابات الرئتان لدى المرضى الذين يعانون من مشاكل تنفسية طويلة الأمد: </strong>قرص إميفلوك ٥۰۰ ملجم ، مرة واحدة في اليوم.</p><p dir="RTL"><strong>الإلتهاب الرئوي: </strong>قرص إميفلوك ٥۰۰ ملجم ، مرة واحدة أو مرتان في اليوم.</p><p dir="RTL"><strong>التهابات المسالك البولية بما في ذلك الكليتان أوالمثانة: </strong>نصف قرص إميفلوك ٥۰۰ ملجم في اليوم.</p><p dir="RTL"><strong>الغدة البروستاتية</strong>:قرص إميفلوك ٥۰۰ ملجم ، مرة واحدة في اليوم.</p><p dir="RTL"><strong>التهابات الجلد وما تحت الجلد بما في ذلك العضلات: </strong>.قرص إميفلوك ٥۰۰ ملجم ، مرة واحدة أو مرتان في اليوم.</p><p dir="RTL"><strong>البالغون والمسنون الذين يعانون من مشاكل في الكلى</strong><strong>:</strong></p><p dir="RTL">طبيبك قد يحتاج أن يعطيك جرعة مخفضة</p><p dir="RTL"><strong>الأطفال والمراهقون</strong><strong>:</strong></p><p dir="RTL">يمنع إعطاء هذا الدواء للأطفال أوالمراهقين .</p><p dir="RTL"><strong>إذا تناولت جرعة زائدة من إميفلوك</strong><strong> :</strong></p><p dir="RTL">إذا تناولت من غير قصد أقراص زائدة عن جرعتك المعتادة ، أخبر طبيبك أو احصل على رأي طبي آخرعلى الفور.</p><p dir="RTL">التأثيرات التالية قد تحدث: نوبات إختلاجية ، الشعور بالإرتباك ، الدوار، انخفاض الوعي ، الرعاش ومشاكل في القلب&ndash; تؤدي إلى عدم انتظام ضربات القلب وكذلك الشعور بالإعتلال (الغثيان) أو الشعور بالحرقة في المعدة.</p><p dir="RTL"><strong>إذا نسيت تناول جرعة إميفلوك</strong><strong> :</strong></p><p dir="RTL">إذا نسيت تناول جرعة خذها حالما تتذكرإلا إذا كان سيحين قريباً وقت جرعتك التالية. لا تتناول جرعة مضاعفة للتعويض عن الجرعة التي فوتها.</p><p dir="RTL"><strong>إذا توقفت عن تناول إميفلوك</strong><strong>:</strong></p><p dir="RTL">لاتتوقف عن تناول إميفلوك لأنك تشعر بتحسن . من المهم أن تأخذ كل الأقراص التي وصفها لك طبيبك.</p><p dir="RTL">إذا توقفت عن تناول أقراصك قبل انتهاء العلاج بكثير، قد تعاودك حالة الخمج أوقد تسوء حالتك أو قد تصبح البكتيريا مقاومة للدواء. إذا كان لديك اسئلة أخرى حول استعمال هذا الدواء ،إطرحهاعلى الطبيب أو الصيدلي الخاص بك .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل الأدوية كلها، يمكن أن يسبب إميفلوك تأثيرات جانبية لاتصيب المرضى كلهم. عادة ما تكون هذه التأثيرات خفيفة إلى معتدلة وغالباً ما تختفي بعد فترة قصيرة.</p><p dir="RTL"><strong>توقف عن تناول إميفلوك واذهب إلى الطبيب أو المستشفى على الفور إذا لاحظت التأثيرات الجانبية الخطيرة التالية</strong><strong>:</strong></p><p dir="RTL"><strong>نادرة جدا ( قد تؤثر فيما يصل إلى </strong><strong>۱</strong><strong> </strong><strong>من بين كل </strong><strong>۱۰۰۰۰</strong><strong> </strong><strong>شخص )</strong></p><p dir="RTL">&bull; إذا كنت تعاني من تفاعلات حساسية . ويمكن أن تشمل الأعراض : طفح جلدي، مشاكل في البلع أو التنفس ، تورم الشفاه ، الوجه ، الحلق، أو اللسان .</p><p dir="RTL">توقف عن تناول إميفلوك واذهب إلى الطبيب على الفور إذا لاحظت التأثيرات الجانبية الخطيرة التالية فقد تحتاج إلى علاج طبي طارئ:</p><p dir="RTL"><strong>نادرة (قد تؤثر فيما يصل إلى </strong><strong>۱</strong><strong> </strong><strong>من بين كل </strong><strong>۱۰۰۰</strong><strong> </strong><strong>شخص )</strong></p><p dir="RTL">&bull; إسهال حاد يمكن أن يحتوي على دماء وقد يترافق مع مغص معدي وحرارة مرتفعة. يمكن أن تكون هذه أعراض لمشكلة حادة في الأمعاء.</p><p dir="RTL">&bull; ألم والتهاب في الأوتار أو الأربطة، والتي يمكن أن يؤدي إلى تمزقها. وتر أخيل يتأثر في معظم الأحيان.</p><p dir="RTL">&bull; نوبات(إختلاجات).</p><p dir="RTL"><strong>نادرة جدآ ( قد تؤثر فيما يصل إلى </strong><strong>۱</strong><strong> </strong><strong>من بين كل </strong><strong>۱۰۰۰۰</strong><strong> </strong><strong>شخص )</strong></p><p dir="RTL">&bull; شعوربالحرق أوالوخزأو الألم أوالخدر. قد تكون هذه الأعراض لمرض يسمى&quot;الاعتلال العصبي&quot;</p><p dir="RTL"><strong>غير معروفة ( نسبة تكرارها لا يمكن تحديدها من البيانات المتاحة)</strong></p><p dir="RTL">&bull; طفح جلدي حاد قد يتضمن تبثرالجلد أو تقشره حول الشفتين والعينين والفم و الأنف والاعضاء التناسلية.</p><p dir="RTL">&bull; فقدان الشهية ، إصفرارالجلد والعينين، بول داكن اللون ، حكة أوالشعور بألم في المعدة(البطن)عند اللمس. قد تكون هذه أعراض مشاكل في الكبد والتي قد تشمل إلى فشل كبدي مميت.</p><p dir="RTL">&bull; إذا شعرت بضعف بصرك أو بوجود أي إعتلال في بصرك أثناء علاجك ب إميفلوك ، إستشر طبيب متخصص في</p><p dir="RTL">العيون فورا.</p><p dir="RTL"><strong>أعلم طبيبك في حال تفاقم أحد التأثيرات التالية أو إذأ استمر لأكثر من بضعة أيام</strong><strong>:</strong></p><p dir="RTL"><strong>شائعة ( قد تؤثر فيما يصل إلى </strong><strong>۱</strong><strong> </strong><strong>من بين كل </strong><strong>۱۰</strong><strong> </strong><strong>أشخاص )</strong></p><p dir="RTL">&bull; اضطرابات في النوم &bull; الصداع، والشعور بالدوار. &bull; الشعور بالإعتلال (الغثيان والقيء) والإسهال.</p><p dir="RTL">&bull; زيادة مستوى انزيمات الكبد في الدم</p><p dir="RTL"><strong>غير شائعة ( قد تؤثر فيما يصل إلى </strong><strong>۱</strong><strong> </strong><strong>من بين كل </strong><strong>۱۰۰</strong><strong> </strong><strong>شخص )</strong></p><p dir="RTL">&bull; تغييرات في أعداد البكتيريا أو الفطريات الأخرى، الإصابة عن طريق الفطريات بداء المبيضات، والتي قد تحتاج إلى علاج.</p><p dir="RTL">&bull; تغييرات في أعداد خلايا الدم البيضاء تظهر في نتائج فحوص الدم (الكريات البيض، فرط الحمضات). &bull; الشعور بالإرهاق (القلق)، والشعور بالإرتباك ، والشعور بالتوتر، والشعور بالنعاس، الارتجاف، وشعور بالدوار. &bull; ضيق في التنفس . &bull; تغييرفي حاسة التذوق ، فقدان الشهية، اضطراب في المعدة أو عسر الهضم (عسر الهضم)، وألم في منطقة المعدة، والشعور بالتطبل (انتفاخ البطن) أو الإمساك.</p><p dir="RTL">&bull; الحكة والطفح الجلدي، الحكة الشديدة أو الشرى، التعرق الشديد (فرط التعرق).</p><p dir="RTL">&bull; آلام المفاصل أو آلام في العضلات . &bull; يمكن لفحوص الدم إظهار نتائج غير طبيعية بسبب مشاكل في الكبد (زيادة البيليروبين) أو مشاكل في الكلى (زيادة الكرياتينين). &bull; ضعف عام.</p><p dir="RTL"><strong>نادرة (قد تؤثر فيما يصل إلى </strong><strong>۱</strong><strong> </strong><strong>من بين كل </strong><strong>۱۰۰۰</strong><strong> </strong><strong>شخص )</strong></p><p dir="RTL">&bull; سهولة التكدم والنزف بسبب انخفاض عدد الصفيحات الدموية (قلة الصفيحات)</p><p dir="RTL">&bull; انخفاض خلايا الدم البيضاء (قلة العدلات)</p><p dir="RTL">&bull; الاستجابة المناعية المبالغ فيها (فرط الحساسية)</p><p dir="RTL">&bull; انخفاص مستوى السكر في الدم (نقص سكر الدم). هذا مهم بالنسبة للمرضى المصابين بداء السكري.</p><p dir="RTL">&bull; رؤية أو سماع أشياء غير موجودة (الهلوسة وجنون العظمة)، والتغيير في الرأي والأفكار (ردود أفعال ذهانية) مع خطر وجود أفكار وميول انتحارية.</p><p dir="RTL">&bull; الشعور بالاكتئاب، والمشاكل النفسية، والشعور بعدم الراحة (استثارة)، أحلام وكوابيس غير طبيعية. &bull; الشعور بالوخز في اليدين والقدمين (مَذَل)</p><p dir="RTL">&bull; مشاكل في السمع (طنين) أو في البصر (عدم وضوح الرؤية).</p><p dir="RTL">&bull; تسارع غير عادي في ضربات قلبك (تَسَرُّعُ القَلْ ب ) أو انخفاض ضغط الدم.</p><p dir="RTL">&bull; ضعف العضلات. هذا هو المهم للمرضى المصابين بالوَهَنٌ العَضَلِيٌّ الوَبيل (مرض نادر في الجهاز العصبي).</p><p dir="RTL">&bull; تغييرات في طريقة عمل الكُلْيَةُ الخاصة بك وأحيانا فشل الكُلْيَةُ الذي قد يكون ناجما عن رد فعل حساسية الكُلْيَةُ يسمى التهاب الكلية الخلالي. &bull; حمى.</p><p dir="RTL"><strong>غير معروفة ( نسبة تكرارها لا يمكن تحديدها من البيانات المتاحة)</strong></p><p dir="RTL">&bull; انخفاض في خلايا الدم الحمراء (فقر الدم)، يمكن أن يسبب شحوب الجلد أو اصفراره بسبب تلف خلايا الدم الحمراء؛ انخفاض في عدد جميع أنواع خلايا الدم (قلة الكريات الشاملة).</p><p dir="RTL">&bull; حمى والتهاب في الحلق وشعور عام بالسقم . وهذا قد يكون راجعا إلى انخفاض عدد خلايا الدم البيضاء (ندرة المحببات). &bull; فقدان الدورة الدموية (صَدْمَةٌ تَأَقِيَّة )</p><p dir="RTL">&bull; زيادة مستوى السكر في الدم (فرط سكر الدم) أو انخفاض السكر في الدم مما يؤدي إلى غيبوبة (غيبوبة نقص سكر الدم). وهذا مهم بالنسبة للمرضى المصابين بداء السكري.</p><p dir="RTL">&bull; تغيير في حاسة الشم ، أوفقدان الشم أو فقدان التذوق (خطل الشم، انعدام الشم ، فقد حاسة الذوق)</p><p dir="RTL">&bull; مشاكل في الحركة والمشي (خلل الحركة، و اضْطِرابٌ خارِجَ الهَرَمِيّ )</p><p dir="RTL">&bull; فقدان مؤقت للوعي أو وضعية الجسم (إغماء).</p><p dir="RTL">&bull; فقدان مؤقت للرؤية ، التهاب العين .</p><p dir="RTL">&bull; ضعف أو فقد السمع.</p><p dir="RTL">&bull; ضربات القلب ذات إيقاع سريع وغير طبيعي ، ضربات القلب ذات إيقاع غير منتظم وتهدد الحياة وتشمل السكتة .( ECG تظهر على مُخَطَّطُ كَهْرَبِيَّةِ القَلْب &quot; QT القلبية ، تغيير في ضربات القلب (وتسمى &quot;إطالة الفاصل الزمني</p><p dir="RTL">&bull; صعوبة في التنفس أو سماع أزيز عند التنفس (تشنج قصبي).</p><p dir="RTL">&bull; ردود أفعال تحسسية في الرئة. &bull; التهاب البنكرياس. &bull; التهاب الكبد.</p><p dir="RTL">&bull; زيادة حساسية الجلد لأشعة الشمس والأشعة فوق البنفسجية (تحسس ضوئي)</p><p dir="RTL">&bull; التهاب في الأوعية التي تحمل الدم في جميع أنحاء الجسم بسبب الحساسية (التهاب الأوعية الدموية).</p><p dir="RTL">&bull; التهاب الأنسجة داخل الفم (التهاب الفم).</p><p dir="RTL">&bull; تمزق العضلات وتدمير العضلات (انحلال الربيدات)</p><p dir="RTL">&bull; احمرار وتورم المفاصل (التهاب المفاصل)</p><p dir="RTL">&bull; الشعور بالألم ويشمل الألم في الظهر والصدر والأطراف.</p><p dir="RTL">&bull; نوبات من البورفيريا لدى المرضى المصابين بداء البورفيريا (مرض إستقلابي نادر جدا)</p><p dir="RTL">&bull; صداع دائم مع أو بدون عدم وضوح الرؤية (فَرْطُ ضَغْطِ الدَّمِ الحَميدُ داخِلَ القِحْف).</p><p dir="RTL">في حال تفاقم أحد التأثيرات الجانبية أو في حال لاحظت أي تأثيرات غيرمذكورة في هذه النشرة، الرجاء إعلام الطبيب أو الصيدلي الخاص بك.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تحفظ الأدوية بعيدا عن رؤية ومتناول الأطفال .يحفظ في درجة حرارة لا تزيد عن ٥۳۰ مئوية في مكان جاف .</p><p dir="RTL">على الشريط والعبوة ، لا تستعمل إميفلوك إذا &quot;EXP&quot; لاتستعمل إميفلوك بعد انقضاء تاريخ الصلاحية المدون بعد كلمة لاحظت إشارات تلف ظاهرة .لا ينبغي رمي الأدوية في المياه المبتذلة أو في النفايات المنزلية. إسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد تحتاج إليها، فمن شأن هذه الإجراءات حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحتوي كل قرص مغلف من إميفلوك على ٥۰۰ ملجم ليفوفلوكساسين( على هيئة ليفوفلوكساسين جزئي الهيدرات ) .<br />المكونات الأخرى هي:<br />قلب القرص : السيليلوز البلوري الدقيق ، السيليكا اللامائية الغروية ، هيبروميللوز ، كروسبوفيدون ، ستيريت<br />المغنيزيوم.<br />غلاف القرص: اوبادراي وردي اللون .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>إميفلوك أقراص مغلفة للإستعمال عبر الفم ، الأقراص وردية اللون ، كبسولية الشكل ، محفور على احد جانبي القرص GP67 &nbsp;وعلى الجانبين خط فاصل لكسر القرص. إميفلوك ٥۰۰ ملجم أقراص مغلفة يتوفر في عبوات تحتوي على شريط واحد به ٥ أو ۷ أقراص.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة جلوبال فارما ذ.م.م.، ص.ب. ۷۲۱٦۸ ، دبي ، الامارات العربية المتحدة .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            (۱۷-۱۱) تم آخر تحديث لهذه النشرة في يوليو ۲۰۱
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                EmiflocTM  500mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each ¬Film-coated tablet of Emifloc contains 500 mg of levofloxacin (as levofloxacin hemihydrate).
For the full list of excipients, see section 6.1

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Pink coloured capsule shaped film coated tablets with GP67 embossed on one side and a break line on both sides.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emifloc is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute bacterial sinusitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute exacerbations of chronic bronchitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Community-acquired pneumonia</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated skin and soft tissue infections</p><p>&nbsp;</p><p>For the above-mentioned infections Emifloc should be used only when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of these infections.</p><p>&nbsp;</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pyelonephritis and complicated urinary tract infections (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Chronic bacterial prostatitis</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncomplicated cystitis (see section 4.4)</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inhalation Anthrax: post exposure prophylaxis and curative treatment (see section 4.4)</p><p>&nbsp;</p><p>Emifloc may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emifloc tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.</p><p>Emifloc tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin;</p><p>given the bioequivalence of the parenteral and oral forms, the same dosage can be used.</p><p><u>Posology</u></p><p>The following dose recommendations can be given for Emifloc:</p><p><em>Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><em>Indication</em></strong></p></td><td style="vertical-align:top"><p><strong>Daily dose regimen</strong></p><p><em>(</em><em>according to severity)</em></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p><p><strong>o</strong><strong>f treatment </strong><em>(</em><em>according to severity)</em></p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>10 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial exacerbations of</p><p>chronic bronchitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Community-acquired pneumonia</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 &ndash; 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250mg once daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic bacterial prostatitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated skin and soft tissue</p><p>infections</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation Anthrax</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>8 weeks</p></td></tr></tbody></table><p>&nbsp;</p><p><em><u>Special populations</u></em></p><p><em>Impaired renal function (creatinine clearance </em>&le; <em>5</em><em>0 ml/min)</em></p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p><p><strong>D</strong><strong>ose regimen</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>250 mg/24 h</strong></p></td><td style="vertical-align:top"><p><strong>500 mg/24 h</strong></p></td><td style="vertical-align:top"><p><strong>500 mg/12 h</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Crea</strong><strong>t</strong><strong>i</strong><strong>n</strong><strong>i</strong><strong>ne </strong><strong>clearance</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>first dose: </em>250 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>first dose: </em>500 mg</p></td><td style="vertical-align:top"><p>&nbsp;</p><p><em>first dose: </em>500 mg</p></td></tr><tr><td style="vertical-align:top"><p>50-20 ml/min</p></td><td style="vertical-align:top"><p><em>then: </em>125 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>: 250 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>: 250 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>19-10 ml/min</p></td><td style="vertical-align:top"><p><em>then: </em>125 mg/48 h</p></td><td style="vertical-align:top"><p><em>then</em>: 125 mg<strong>/</strong>24 h</p></td><td style="vertical-align:top"><p><em>then</em>: 125 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10 ml/min (including haemodialysis and CAPD) 1</p></td><td style="vertical-align:top"><p><em>then: </em>125 mg/48 h</p></td><td style="vertical-align:top"><p><em>then</em>: 125 mg/24 h</p></td><td style="vertical-align:top"><p><em>then</em>: 125 mg/24 h</p></td></tr></tbody></table><p>1 No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).</p><p><em>Impaired liver function</em></p><p>No adjustment of dose is required since levofloxacin is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys.</p><p><em>Elderly Population</em></p><p>No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (See section 4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).</p><p><em>Paediatric population</em></p><p>Emifloc is contraindicated in children and growing adolescents (see section 4.3). <u>Method of administration</u></p><p>Emifloc tablets should be swallowed without crushing and with sufficient amount of liquid. They may be divided at the score line to adapt the dose. The tablets may be taken during meals or between meals. Emifloc tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or magnesium containing buffering agents), </em>and sucralfate administration, since reduction of absorption can occur (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin tablets must not be used:

•	in patients hypersensitive to levofloxacin or other quinolones or any of the excipients listed in section 6.1,
•	in patients with epilepsy,
•	in patients with history of tendon disorders related to fluoroquinolone administration,
•	in children or growing adolescents,
•	during pregnancy,
•	in breast-feeding women.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Methicillin-resistant <em>S. aureus </em>are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).</p><p>Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.</p><p>Resistance to fluoroquinolones of <em>E</em><em>. coli </em>&ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in <em>E</em><em>. coli </em>to fluoroquinolones.</p><p>Inhalation Anthrax: Use in human is based on <em>in vitro Bacillus anthracis </em>susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p><em>Tendinitis and tendon rupture</em></p><p>Tendinitis may rarely occur. It most frequently involves the Achilles tendon and may lead to tendon rupture. Tendinitis and tendon rupture, sometimes bilateral, may occur within 48 hours of starting treatment with levofloxacin and have been reported up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in patients aged over 60 years, in patients receiving daily doses of 1000 mg and in patients using corticosteroids. The daily dose should be adjusted in elderly patients based on creatinine clearance (see section 4.2). Close monitoring of these patients is therefore necessary if they are prescribed levofloxacin. All patients should consult their physician if they experience symptoms of tendinitis. If tendinitis is suspected, treatment with levofloxacin must be halted immediately, and appropriate treatment (e.g. immobilisation) must be initiated for the affected tendon (see sections 4.3 and 4.8).</p><p><em>C</em><em>l</em><em>ostridium difficile-associated disease</em></p><p>Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of <em>C</em><em>l</em><em>ostridium difficile</em>-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.</p><p><em>Patients predisposed to seizures</em></p><p>Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive&nbsp; seizures (see section 4.8), treatment with levofloxacin should be discontinued.</p><p><em>Patients with G-6- phosphate dehydrogenase deficiency</em></p><p>Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial</p><p>agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><p><em>Patients with renal impairment</em></p><p>Since levofloxacin is excreted mainly by the kidneys, the dose of Emifloc should be adjusted in patients with renal impairment (see section 4.2).</p><p><em>Hypersensitivity reactions</em></p><p>Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.</p><p><em>Severe bullous reactions</em></p><p>Cases of severe bullous skin reactions such as Stevens-Johnson syndrome or toxic epidermal necrolysis have been reported with levofloxacin (see section 4.8). Patients should be advised to contact their doctor immediately prior to continuing treatment if skin and/or mucosal reactions occur.</p><p><em>D</em><em>ysglycaemia</em></p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients,&nbsp; careful monitoring of blood glucose is recommended (see section 4.8).</p><p><em>Prevention of photosensitisation</em></p><p>Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.</p><p><em>Patients treated with Vitamin K antagonists</em></p><p>Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).</p><p><em>Psychotic reactions</em></p><p>Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self- endangering behaviour- sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p><em>QT interval prolongation</em></p><p>Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>-&nbsp; congenital long QT syndrome</p><p>-&nbsp; concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</p><p>-&nbsp; uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)</p><p>-&nbsp; cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including</p><p>levofloxacin, in these populations. (See sections 4.2 <em>Elder</em><em>l</em>y, 4.5, 4.8, and 4.9).</p><p><em>Peripheral neuropathy</em></p><p>Peripheral sensory neuropathy and peripheral sensory motor neuropathy have been reported in patients receiving fluoroquinolones, including levofloxacin, which can be rapid in its onset (see section 4.8). Levofloxacin should be discontinued if the patient experiences symptoms of neuropathy in order to prevent the development of an irreversible condition.</p><p><em>Hepatobiliary disorders</em></p><p>Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</p><p><em>Exacerbation of myasthenia gravis</em></p><p>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.</p><p><em>Vision disorders</em></p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p><em>Superinfection</em></p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non- susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p><em>Interference with laboratory tests</em></p><p>In patients treated with levofloxacin, determination of opiates in urine may give false- positive results. It may be necessary to confirm positive opiate screens by more specific method.</p><p>Levofloxacin may inhibit the growth of <em>Mucobacterium tuberculosis </em>and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effect of other medicinal products on Emifloc</u></p><p><em>Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine</em></p><p>Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or magnesium containing buffering agents) </em>are administered concomitantly with Emifloc tablets. Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, or didanosine (<em>only didanosine formulations with aluminium or &nbsp;magnesium containing buffering agents) </em>should not be taken 2 hours before or after Emifloc tablet administration (see section 4.2). Calcium salts have a minimal effect on the oral absorption of levofloxacin.</p><p><em>Sucralfate</em></p><p>The bioavailability of Emifloc tablets is significantly reduced when administered together with sucralfate. &nbsp;If the patient is to receive both sucralfate and Emifloc, it is best to administer sucralfate 2 hours after the Emifloc tablet administration (see section 4.2).</p><p><em>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</em></p><p>No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study.&nbsp;&nbsp; However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold. Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.</p><p><em>Probenecid and cimetidine</em></p><p>Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). &nbsp;This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin.&nbsp; However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance. Caution should be exercised when levofloxacin is coadministered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.</p><p><em>O</em><em>t</em><em>her relevant information</em></p><p>Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.</p><p><u>Effect of Emifloc on other medicinal products</u></p><p><em>Ciclosporin</em></p><p>The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.</p><p><em>Vitamin K antagonists</em></p><p>Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).</p><p><em>Drugs known to prolong QT interval</em></p><p>Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).</p><p><em>O</em><em>t</em><em>her relevant information</em></p><p>In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.</p><p><u>Other forms of interactions</u></p><p><em>Food</em></p><p>There is no clinically relevant interaction with food. &nbsp;Emifloc tablets may therefore be administered regardless of food intake.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pregnancy</em></p><p>There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see sections 4.3 and 5.3).</p><p><em>Breast-feeding</em></p><p>Emifloc is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however, other fluoroquinolones are excreted in breast milk. In the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).</p><p><em>F</em><em>ertility</em></p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&rsquo;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.</p><p>Frequencies are defined using the following convention: very common (&nbsp;1/10), common &ge;&nbsp;( &nbsp;1/100, &nbsp;&lt;1/10), &nbsp;uncommon &nbsp;(1/1000, &nbsp;&lt;1/100), &nbsp;rare &nbsp;(1/10000, &nbsp;&lt;1/1000), &nbsp;very &nbsp;rare&nbsp;(&lt;1/10000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>ommon</strong></p></td><td style="vertical-align:top"><p><strong>Unco</strong><strong>m</strong><strong>mon</strong></p></td><td style="vertical-align:top"><p><strong>Ra</strong><strong>re</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>No</strong><strong>t known (cannot be</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>class</strong></p></td><td style="vertical-align:top"><p><strong>( &nbsp;1/100 to</strong></p></td><td style="vertical-align:top"><p><strong>( &nbsp;1/1,000 to</strong></p></td><td style="vertical-align:top"><p><strong>( &nbsp;1/10,000 to</strong></p></td><td style="vertical-align:top"><p><strong>estimated from</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;1/10 )</strong></p></td><td style="vertical-align:top"><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and</p><p>infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fungal</p><p>infection including</p><p>Candida</p><p>infection</p><p>Pathogen resistance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and</p><p>lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Neutropenia</p></td><td colspan="3" style="vertical-align:top"><p>Pancytopenia</p><p>Agranulocytosis Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p><p>Hypersensitivity (see section 4.4)</p></td><td colspan="3" style="vertical-align:top"><p>Anaphylactic shocka</p><p>Anaphylactoid shocka (see section 4.4)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&ge;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&ge;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&ge;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>ommon ( &nbsp;1/100 to</strong></p><p><strong>&lt;1/10 )</strong></p></td><td style="vertical-align:top"><p><strong>Unco</strong><strong>m</strong><strong>mon ( &nbsp;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Ra</strong><strong>re</strong></p><p><strong>( &nbsp;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>No</strong><strong>t known (cannot be estimated from</strong></p><p><strong>available data)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and</p><p>nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Hypoglycaemia</p><p>particularly in diabetic patients (see section 4.4)</p></td><td colspan="3" style="vertical-align:top"><p>Hyperglycaemia</p><p>Hypoglycaemic coma (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric</p><p>disorders</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety</p><p>Confusional state Nervousness</p></td><td style="vertical-align:top"><p>Psychotic</p><p>reactions (with</p><p>e.g. hallucination, paranoia)</p><p>Depression Agitation</p><p>Abnormal dreams Nightmares</p></td><td colspan="3" style="vertical-align:top"><p>Psychotic disorders</p><p>with self-endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system</p><p>disorders</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence</p><p>Tremor Dysgeusia</p></td><td style="vertical-align:top"><p>Convulsion (see</p><p>sections 4.3 and</p><p>4.4)</p><p>Paraesthesia</p></td><td colspan="3" style="vertical-align:top"><p>Peripheral sensory</p><p>neuropathy (see section 4.4)</p><p>Peripheral sensory motor neuropathy (see section 4.4)</p><p>Parosmia including anosmia</p><p>Dyskinesia Extrapyramidal</p><p>disorder</p><p>Ageusia Syncope</p><p>Benign intracranial hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual</p><p>disturbances such as blurred vision</p><p>(see section 4.4)</p></td><td colspan="3" style="vertical-align:top"><p>Transient vision loss</p><p>(see section 4.4), uveitis</p></td></tr><tr><td style="vertical-align:top"><p>Ear and</p><p>Labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td colspan="3" style="vertical-align:top"><p>Hearing loss</p><p>Hearing impaired</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>Palpitation</p></td><td colspan="3" style="vertical-align:top"><p>Ventricular tachycardia,</p><p>which may result in cardiac arrest Ventricular arrhythmia, and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation),</p><p>Electrocardiogram QT prolonged (see sections</p><p>4.4 and 4.9)</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&ge;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&ge;</p></td></tr></tbody></table><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>&ge;</p></td></tr></tbody></table><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>ommon</strong></p></td><td style="vertical-align:top"><p><strong>Unco</strong><strong>m</strong><strong>mon</strong></p></td><td style="vertical-align:top"><p><strong>Ra</strong><strong>re</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>No</strong><strong>t known (cannot be</strong></p></td><td rowspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>class</strong></p></td><td style="vertical-align:top"><p><strong>( &nbsp;1/100 to</strong></p></td><td style="vertical-align:top"><p><strong>( &nbsp;1/1,000 to</strong></p></td><td style="vertical-align:top"><p><strong>( &nbsp;1/10,000 to</strong></p></td><td style="vertical-align:top"><p><strong>estimated from</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>&lt;1/10 )</strong></p></td><td style="vertical-align:top"><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p><strong>available data)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Vascular</p><p>disorders</p></td><td style="vertical-align:top"><p><em><u>Applies to iv</u></em></p><p><em><u>form only:</u></em></p><p>Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory,</p><p>thoracic and mediastinal</p><p>disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Bronchospasm,</p><p>Pneumonitis allergic</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal</p><p>disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Vomiting Nausea</p></td><td style="vertical-align:top"><p>Abdominal</p><p>pain Dyspepsia</p><p>Flatulence Constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Diarrhoea &ndash;</p><p>haemorrhagic which in very rare cases may be</p><p>indicative of enterocolitis, including</p><p>pseudomembranous colitis (see section 4.4) Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary</p><p>disorders</p></td><td style="vertical-align:top"><p>Hepatic</p><p>enzyme increased (ALT/AST,</p><p>alkaline phosphatase,</p><p>GGT)</p></td><td style="vertical-align:top"><p>Blood</p><p>bilirubin increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Jaundice and severe</p><p>liver injury, including cases with fatal acute liver failure, primarily in patients with severe underlying diseases (see section 4.4) Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and</p><p>subcutaneous tissue disordersb</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus Urticaria Hyperhidrosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Toxic epidermal</p><p>necrolysis Stevens-Johnson</p><p>syndrome</p><p>Erythema multiforme Photosensitivity</p><p>reaction (see section</p><p>4.4)</p><p>Leukocytoclastic vasculitis</p><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal</p><p>and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendon disorder</p><p>(see sections 4.3</p><p>and 4.4) including tendinitis (e.g.</p><p>Achilles tendon)</p><p>Muscular weakness which may be of importance in patients with myasthenia gravis (see section 4.4)</p></td><td colspan="3" style="vertical-align:top"><p>Rhabdomyolysis</p><p>Tendon rupture (e.g. Achilles tendon) (see sections 4.3 and 4.4) Ligament rupture Muscle rupture Arthritis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and</p><p>urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood</p><p>creatinine increased</p></td><td style="vertical-align:top"><p>Renal failure acute</p><p>(e.g. due to interstitial</p><p>nephritis)</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>C</strong><strong>ommon ( &nbsp;1/100 to</strong></p><p><strong>&lt;1/10 )</strong></p></td><td style="vertical-align:top"><p><strong>Unco</strong><strong>m</strong><strong>mon ( &nbsp;1/1,000 to</strong></p><p><strong>&lt;1/100)</strong></p></td><td style="vertical-align:top"><p><strong>Ra</strong><strong>re</strong></p><p><strong>( &nbsp;1/10,000 to</strong></p><p><strong>&lt;1/1,000)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>No</strong><strong>t known (cannot be estimated from available data)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><em><u>Applies to iv</u></em><em> <u>form only:</u></em></p><p>Infusion site reaction (pain, reddening)</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td colspan="3" style="vertical-align:top"><p>Pain (including pain in back, chest, and extremities)</p></td></tr></tbody></table><p>&nbsp;Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose</p><p>b Mucocutaneous reactions may sometimes occur even after the first dose</p><p>Other undesirable effects which have been associated with fluoroquinolone administration include:</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; attacks of porphyria in patients with porphyria.</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions at:</p><p>&nbsp;&bull; Saudi Arabia: The National Pharmacovigilance and Drug Safety Centre (NPC) ,</p><p>Fax: +966-11-205-7662,</p><p>Call NPC at +966-11-2038222,</p><p>Exts 2317-2356-2340. Reporting Hotline: 19999,</p><p>E-mail: npc.drug@sfda.gov.sa ,</p><p>Website: www.sfda.gov.sa/npc</p><p>&bull; Other GCC States: Please contact the relevant competent authority</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of Emifloc tablets are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.</p><p>CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body.&nbsp; No specific antidote exists.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones ATC code: J01MA12</p><p>Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin.</p><p><em>Mechanism of action</em></p><p>As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.</p><p><em>PK/P</em><em>D relationship</em></p><p>The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).</p><p><em>Mechanism of resistance</em></p><p>Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in <em>Pseudomonas </em><em>aeruginosa) </em>and efflux mechanisms may also affect susceptibility to levofloxacin.</p><p>Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.</p><p><em>Breakpoints</em></p><p>The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/l).</p><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><p><u>Commonly susceptible species</u></p><p><u>Aerobic Gram-positive bacteria</u></p><p><em>Bacillus anthracis</em></p><p><em>Staphylococcus aureus methicillin-susceptible Staphylococcus saprophyticus</em></p><p><em>Stre</em><em>p</em><em>t</em><em>o</em><em>c</em><em>oc</em><em>c</em><em>i</em><em>, group C and G Streptococcus agalactiae</em></p><p><em>Streptococcus pneumoniae Streptococcus pyogenes</em></p><p><strong><em><u>Aerobic Gram- negative bacteria</u></em></strong><strong><em> </em></strong><em>Eikenella corrodens Haemophilus influenzae Haemophilus para-influenzae</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Moraxella catarrhalis Pasteurella multocida Proteus vulgaris Providencia rettgeri</em></p><p><u>Anaerobic bacteria</u></p><p><em>Peptostreptococcus</em></p><p><u>Other</u></p><p><em>Chlamydop</em><em>h</em><em>i</em><em>l</em><em>a pneumoniae Chlamydophila psittaci Chlamydia trachomatis Legionella&nbsp; pneumophila Mycoplasma pneumoniae Mycoplasma hominis Ureaplasma urealyticum</em></p><p><u>Species for which acquired resistance may be a problem</u></p><p><u>Aerobic Gram-positive bacteria</u></p><p><em>E</em><em>nterococcus faecalis</em></p><p><em>Staphylococcus aureus </em>methicillin-resistant# Coagulase negative <em>Staphylococcus spp</em></p><p><strong><em><u>Aerobic Gram- negative bacteria</u></em></strong><strong><em> </em></strong><em>Acinetobacter baumannii Citrobacter freundii Enterobacter aerogenes</em></p><p><em>E</em><em>nterobacter cloacae</em></p><p><em>Escherichia coli Klebsiella pneumoniae Morganella morganii Proteus mirabilis Providencia stuartii Pseudomonas aeruginosa Serratia marcescens</em></p><p><u>Anaerobic bacteria</u></p><p><em>B</em><em>acteroides fragilis</em></p><p><strong><u>Inherently Resistant Strains</u></strong></p><p><u>Aerobic Gram-positive bacteria</u></p><p><em>E</em><em>nterococcus faecium</em></p><p># Methicillin-resistant <em>S. aureus </em>are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 - 2 h. The absolute bioavailability is 99 - 100 %.</p><p>Food has little effect on the absorption of levofloxacin.</p><p>Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.</p><p><u>Distribution</u></p><p>Approximately 30 - 40 % of levofloxacin is bound to serum protein.</p><p>The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><p><u>Penetration into tissues and body fluids:</u></p><p>Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.</p><p><u>Biotransformation</u></p><p>Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl- levofloxacin and levofloxacin N-oxide. These metabolites account for &lt;5 % of the dose and are excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.</p><p><u>Elimination</u></p><p>Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t&frac12; : 6 - 8 h). Excretion is primarily by the renal route (&gt;85 % of the administered dose).</p><p>The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/-29.2 ml/min.</p><p>There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.</p><p><u>Linearity</u></p><p>Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg. <u>Special populations</u></p><p><em>Subjects with renal insufficiency</em></p><p>The pharmacokinetics of levofloxacin are affected by renal impairment. &nbsp;With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:</p><p>Pharmacokinetics in renal insufficiency following single oral 500 mg dose</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Clcr [ml/mi</p><p>n]</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>20 -</p><p>49</p></td><td style="vertical-align:top"><p>50 -</p><p>80</p></td></tr><tr><td style="vertical-align:top"><p>ClR [ml/mi</p><p>n]</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p>t1/2&nbsp;&nbsp; &nbsp;[h]</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p>&nbsp;</p><p><em>Elderly subjects</em></p><p>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.</p><p><em>G</em><em>ender differences</em></p><p>Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. &nbsp;There is no evidence that these gender differences are of clinical relevance.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.</p><p>Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells <em>in vitro. </em>These effects can be attributed to inhibition of topoisomerase II. &nbsp;<em>In vivo </em>tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenity study.</p><p>In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. &nbsp;These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet core:</p><p>Microcrystalline cellulose,</p><p>Colloidal Anhydrous Silica,</p><p>Hypromellose,</p><p>Crospovidone,</p><p>Magnesium Stearate.</p><p>&nbsp;</p><p>Tablet coating:</p><p>Opadry Pink</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not Store above 30&deg;C. Store in a dry place.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Emifloc 500 is available in Aluminum/ PVC-PVDC clear blisters in packs of 5&rsquo;s and 7&rsquo;s.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A score line allows adaptation of the dose in patients with impaired renal function.</p><p>As for all medicines, any unused medicinal product should be disposed of accordingly and in compliance with local environmental regulations</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Globalpharma Co. L.L.C. Dubai Investment Park, Jebel Ali, Dubai, United Arab Emirates
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 November 2017
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>